Celgene and Bristol-Myers Squibb have scored exits as the oncology drug developer priced an upsized offering above its range.

JD.com's medical products spinoff has gone public in Hong Kong's largest initial public offering this year, valuing it at close to $29bn.

Sistema invested $67.5m in the e-commerce platform developer alongside an upsized initial public offering in which it floated above its range.

The WuXi AppTec, Celgene, Taikang and Tigermed-backed cancer drug developer went public in Hong Kong at the top of its range.

TDK Ventures, Paz Oil and Landa Ventures-backed hydrogen and ammonia fuel cell technology developer raised $60.7m in an Israel flotation.

William Hill sold $11.5m shares in the $81.7m initial public offering but remains the lottery software producer's largest shareholder.

Berkeley Catalyst Fund-backed gene therapy developer 4D Molecular Therapeutics withdrew its last attempt in July.

Chint, Sinopec, Intel, Wanxiang and Lenovo-backed process automation technology producer Supcon has priced an offering on Shanghai's Star Exchange.

Chronic illness drug developer Sigilon Therapeutics, co-founded by MIT and UIC researchers, has filed to go public after raising almost $200m in funding.

WuXi AppTec and Juno Therapeutics' joint cancer immunotherapy venture has listed on the Hong Kong Stock Exchange.